Watch CELZ. Know when insiders buy.
One email the day a filing lands. Free.
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
0.74
−0.03 −4.39%
USD · close Oct 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.9MP/E —DIV YIELD —FCF YIELD —REV TTM $3K −50.0%NET INCOME −$6MNET DEBT $639K52W 0.65 – 5.59SEC XBRL · TTM TO Invalid Date
How CELZ rewrote its risk factors
Text kept
91%
of sentences unchanged
Added
9
new sentences
Dropped
9
sentences removed
Length
−3
words, now 6,513
New in FY2025
- We have incurred an operating loss of approximately $6.1 million for the year ended December 31, 2025, and a loss of approximately $5.7 million for the year ended December 31, 2024, respectively.
- Even with the proceeds from our securities offerings, we will need additional capital to fund our operations as planned.
- For the year ended December 31, 2025, our operations used approximately $5.9 million in cash.
- Cash used in operations consisted primarily of cash on hand and cash raised in our securities offerings, including upon exercise of warrants in our warrant exercise transactions.
- At December 31, 2025, we had a combined cash, and short-term U.S. treasuries balance of approximately $7.2 million.
- Although we generated gross proceeds in excess of $40 million from our 2021, 2022, 2024, and 2025 securities offerings, we will need additional capital to maintain our operations, continue our research and development programs, conduct clinical trials, seek regulatory approvals and manufacture and market our products.
- Revenues generated from sales of our CaverStem ® kits were only $6,000 and $11,000 for the years ended December 31, 2025, and 2024, respectively.
- We expect to continue to incur significant financial losses in the future as we proceed with our Type I Diabetes (CELZ-201 CREATE-1) clinical trial, our AlloStemSpine ® Chronic Lower Back Pain (CELZ-201 ADAPT) clinical trial, and our other planned clinical trials.
- We have received the necessary regulatory approval for our Type I Diabetes (CELZ-201 CREATE-1) clinical trial and our AlloStemSpine ® Chronic Lower Back Pain (CELZ-201 ADAPT) clinical trial, which are in process.
Gone since FY2024
- We have incurred an operating loss of approximately $5.7 million for the year ended December 31, 2024, and a loss of approximately $5.6 million for the year ended December 31, 2023, respectively.
- Even with the proceeds from our recent securities offerings, we will need additional capital to fund our operations as planned.
- For the year ended December 31, 2024, our operations used approximately $5.3 million in cash.
- Cash used in operations consisted primarily of cash on hand and cash raised in our December 2021 public offering, our May 2022 private offering and our December 2024 private offering.
- At December 31, 2024, we had a combined cash, and short-term U.S. treasuries balance of approximately $5.9 million.
- Although we generated gross proceeds in excess of $32 million from our 2021, 2022 and 2024 securities offerings, we will need additional capital to maintain our operations, continue our research and development programs, conduct clinical trials, seek regulatory approvals and manufacture and market our products.
- Revenues generated from sales of our CaverStem ® kits were only $11,000 and $9,000 for the years ended December 31, 2024, and December 31, 2023, respectively.
- We expect to continue to incur significant financial losses in the future as we seek to proceed with our Type I Diabetes (CELZ-201 CREATE-1) clinical trial, our AlloStemSpine ® Chronic Lower Back Pain (CELZ-201 ADAPT) clinical trial, and our other planned clinical trials.
- We have received the necessary regulatory approval for our Type I Diabetes (CELZ-201 CREATE-1) clinical trial and our AlloStemSpine ® Chronic Lower Back Pain (CELZ-201 ADAPT) clinical trial.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.